Fortress Biotech's Total Assets for the quarter that ended in Dec. 2023 was $167.53 Mil.
Warning Sign:
If a company builds assets at 8% a year, faster than its revenue growth rate of 4.6% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Fortress Biotech's average Total Assets Growth Rate was -25.40% per year.
During the past 3 years, the average Total Assets Growth Rate was -4.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 8.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 36.00% per year.
During the past 13 years, Fortress Biotech's highest 3-Year average Total Assets Growth Rate was 349.80%. The lowest was -4.70%. And the median was 28.85%.
The historical data trend for Fortress Biotech's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Fortress Biotech's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortress Biotech (NAS:FBIO) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Fortress Biotech's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Fortress Biotech Total Assets Related Terms
Thank you for viewing the detailed overview of Fortress Biotech's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Fortress Biotech (Fortress Biotech) Business Description
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FBIO has been successfully added to your 